Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

Rhea-AI Summary

Fresh2 Group Ltd. (formerly AnPac Bio-Medical Science Co., Ltd.) will change its ticker symbol on the Nasdaq Stock Market from 'ANPC' to 'FRES' effective May 22, 2023. The change reflects the company's shift towards a business-to-business e-commerce food platform focused on Asian sourced food products.

Positive

• Fresh2 Group Ltd. is transitioning to a new ticker symbol 'FRES' to align with its new brand identity in the U.S. food market and its focus on the business-to-business food trade and delivery platform. The company believes it is well positioned to increase its presence in the new business sector with a scalable business model.

Negative

• None.

Ticker symbol change effective at the market open May 22, 2023

NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has traded under the ticker "ANPC" since the Company's initial public offering in 2020.

Mr. Haohan Xu, Co-CEO of the Company commented: "Transitioning to the ticker 'FRES' is the most recent step we have taken toward our strategic initiative to focus on the recently engaged new business line of business-to-business food trade and delivery platform for U.S. local restaurants and supermarkets. The ticker symbol change aligns with our new brand identity in the U.S. food market and reflects our vision for the future. We believe that we are well positioned to increase our presence in the new business sector with scalable business model and look forward to our future with confidence."

No action by the company's shareholders is required with respect to the ticker symbol change. The company's CUSIP number will remain unchanged.

About Fresh2 Group Limited

Fresh2 Group Limited is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2023. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, Fresh2 performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. The Company is entering the business-to-business e-commerce food business with the formation of its wholly-owned subsidiary Fresh2 Technology Inc and the acquisition of Fresh2 Ecommerce Inc.

For more information, please visit: https://fresh2.co/investors.

For investor and media inquiries, please contact:

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-917-609-0333 (U.S.)
Email: tina.xiao@ascent-ir.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq Listing Rules including maintaining our listing on the Nasdaq Capital Market, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. A number of these risks along with additional discussion of forward-looking statements, are set forth in the Company's Annual Report on Form 20-F and other reports filed with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the COVID19 virus and the impact it will have on the Company's operations, global supply chains and economic activity in general. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

View original content:https://www.prnewswire.com/news-releases/fresh2-group-ltd-announces-nasdaq-ticker-symbol-change-from-anpc-to-fres-301829770.html

SOURCE Fresh2 Group Limited

FAQ

What is the new ticker symbol for Fresh2 Group Ltd.?

The new ticker symbol for Fresh2 Group Ltd. is 'FRES'.

What is the focus of Fresh2 Group Ltd.'s new business line?

Fresh2 Group Ltd.'s new business line is a business-to-business e-commerce food platform focused on the sale of Asian sourced food products.

When will the ticker symbol change be effective?

The ticker symbol change will be effective on May 22, 2023.